Eli Lilly’s (LLY) blood cancer (leukemia) treatment called Jaypirca has shown promising results in a clinical trial. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, ...
Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized treatment for hematologic malignancies, butacquired BTK mutations often ...
Sept 8 (Reuters) - Eli Lilly's (LLY.N), opens new tab approved blood cancer therapy Jaypirca helped delay progression of the disease in previously untreated patients in a late-stage study, advancing ...
Gertrude B. Elion, a chemist working in the research laboratories of Burroughs Wellcome, revolutionized childhood cancer ...
The leading Chronic Myeloid Leukemia Companies such as Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, ...
The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.
Jason Weiner has benefited from the opportunity to participate in a myelofibrosis clinical trial at MSK. He is shown here with his wife, Cori, children Dominik, Kasia, and Damian, and dog Babka around ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback